Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
(RTTNews) - While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
For fiscal 2023, the company continues to project total revenue between $15.5 billion and $16.0 billion. On average, nine analysts polled by Thomson Reuters expect the company to report revenues of $15.60 billion for the year.
The company also said its Board of Directors declared a quarterly dividend of $0.12 for each issued and outstanding share of the company's common stock, payable on September 15, 2023, to shareholders of record at the close of business on August 24, 2023.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%
Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RTTNews
|
289天前
Viatris Guides FY24 In Line With Estimates - Update
While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
322天前
Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the first quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
RTTNews
|
618天前
Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise
Healthcare company Viatris Inc. (VTRS) announced Monday that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.
RTTNews
|
800天前
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews
|
800天前
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris
Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews
|
846天前
Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.
RTTNews
|
891天前
TSX Up Nearly 1% As Interest Rate Concerns Drop
The Canadian market is up firmly in positive territory Wednesday afternoon as U.S. consumer price inflation data has raised hopes the Federal Reserve will lower interest rates in its next meeting, or in March 2025.
Technology, real estate, financials and healthcare stocks notably higher. A few stocks from consumer staples, industrials and materials sectors are also up, while shares from the rest
RTTNews
|
6小時3分鐘前
